SunTrust Banks Analysts Raise Earnings Estimates for Bausch Health Companies Inc (NYSE:BHC)

Bausch Health Companies Inc (NYSE:BHC) – Stock analysts at SunTrust Banks lifted their FY2019 earnings per share estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Monday, August 12th. SunTrust Banks analyst G. Gilbert now expects that the company will post earnings of $4.13 per share for the year, up from their previous estimate of $3.98. SunTrust Banks also issued estimates for Bausch Health Companies’ Q4 2019 earnings at $1.04 EPS.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.03). Bausch Health Companies had a negative net margin of 10.88% and a positive return on equity of 52.12%. The firm had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same quarter last year, the business earned $0.93 earnings per share. The business’s quarterly revenue was up 1.1% on a year-over-year basis.

Other equities analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research report on Tuesday, May 21st. Barclays set a $28.00 price objective on shares of Bausch Health Companies and gave the company a “buy” rating in a research report on Monday, July 8th. TD Securities upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Thursday. Wolfe Research began coverage on shares of Bausch Health Companies in a research report on Friday, July 19th. They set an “outperform” rating and a $31.00 target price on the stock. Finally, HC Wainwright boosted their target price on shares of Bausch Health Companies from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $29.68.

NYSE:BHC opened at $20.88 on Wednesday. The firm’s fifty day moving average price is $23.79 and its 200 day moving average price is $23.91. Bausch Health Companies has a 1-year low of $17.20 and a 1-year high of $28.45. The company has a debt-to-equity ratio of 8.94, a current ratio of 1.21 and a quick ratio of 0.92. The firm has a market cap of $7.85 billion, a price-to-earnings ratio of 5.19, a price-to-earnings-growth ratio of 0.26 and a beta of 0.76.

In other Bausch Health Companies news, EVP Christina Ackermann sold 3,968 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $24.81, for a total transaction of $98,446.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.87% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of BHC. Citizens Financial Group Inc RI acquired a new position in shares of Bausch Health Companies during the 2nd quarter worth $28,000. Investors Research Corp raised its stake in shares of Bausch Health Companies by 85.7% during the 2nd quarter. Investors Research Corp now owns 1,300 shares of the company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. Beutel Goodman & Co Ltd. acquired a new position in shares of Bausch Health Companies during the 1st quarter worth $38,000. Providence Capital Advisors LLC acquired a new position in shares of Bausch Health Companies during the 1st quarter worth $49,000. Finally, Asset Planning Services Ltd. acquired a new position in shares of Bausch Health Companies during the 2nd quarter worth $55,000. Institutional investors own 53.70% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Further Reading: Understanding Price to Earnings Ratio (PE)

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.